New Study Medication for Patients with Secondary Progressive Multiple Sclerosis

This is a study to evaluate the efficacy and safety of a new study medication in patients with Secondary Progressive Multiple Sclerosis.

  • Must have a diagnosis of Secondary Progressive MS of at least 6 months duration, with or without relapses
  • This is an oral investigational medication
  • Ages 18-60
  • No cardiac history
  • No Tysabri© within the past 6 months.  No Gilenya© within the past 2 months or taken for more than 6 months duration
  • Must be able to walk at least 20 meters (bilateral canes or crutches are ok to use)
  • Study lasts approximately 23-42 months.